Cantor Fitzgerald Boosts Earnings Estimates for MiMedx Group

Key Points

• Cantor Fitzgerald has raised its FY2025 EPS estimate for MiMedx Group to $0.25 per share, while maintaining an "Overweight" rating and a price target of $12.00.
• MiMedx Group's recent quarterly earnings exceeded expectations, reporting $0.10 EPS and revenue of $98.61 million, surpassing the consensus estimate of $90.79 million.
• Shares of MiMedx Group are currently trading up 10.3% and have shown significant volatility, with a one-year low of $5.47 and a high of $10.14.

MiMedx Group, Inc (NASDAQ:MDXG - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for MiMedx Group in a report issued on Thursday, July 31st. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of $0.25 per share for the year, up from their prior forecast of $0.24. Cantor Fitzgerald currently has a "Overweight" rating and a $12.00 target price on the stock. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share. Cantor Fitzgerald also issued estimates for MiMedx Group's FY2026 earnings at $0.33 EPS.

Separately, Wall Street Zen raised MiMedx Group from a "hold" rating to a "strong-buy" rating in a report on Saturday.

MiMedx Group Price Performance

MiMedx Group stock traded down $0.08 during mid-day trading on Friday, hitting $7.08. 225,766 shares of the company were exchanged, compared to its average volume of 692,807. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14. The business's 50 day simple moving average is $6.45 and its two-hundred day simple moving average is $7.23. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. The company has a market capitalization of $1.05 billion, a P/E ratio of 33.69 and a beta of 1.79.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.06 by $0.04. The firm had revenue of $98.61 million during the quarter, compared to analysts' expectations of $90.79 million. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MDXG. Paradigm Capital Management Inc. NY increased its holdings in shares of MiMedx Group by 0.5% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock worth $45,082,000 after buying an additional 22,131 shares in the last quarter. Cannell Capital LLC raised its holdings in shares of MiMedx Group by 1.1% during the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock worth $35,012,000 after acquiring an additional 40,235 shares during the period. First Light Asset Management LLC increased its stake in MiMedx Group by 3.3% in the 1st quarter. First Light Asset Management LLC now owns 3,453,074 shares of the company's stock valued at $26,243,000 after buying an additional 109,213 shares during the last quarter. Renaissance Technologies LLC increased its stake in MiMedx Group by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after buying an additional 280,327 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of MiMedx Group by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock valued at $17,338,000 after acquiring an additional 238,075 shares during the period. Institutional investors and hedge funds own 79.15% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.